Main Menu


Publications Highlights View all by category

Types of Publications

Journal Articles

Gregucci, F. Spada, S. Barcellos-Hoff, M.H. Bhardwaj, N. Chan Wah Hak, C. Fiorentino, A. Guha, C. Guzman, M.L. Harrington, K. Herrera, F.G. Honeychurch, J. Hong, T. Iturri, L. Jaffee, E. Karam, S.D. Knott, S.R. Koumenis, C. Lyden, D. Marciscano, A.E. Melcher, A. Mondini, M. Mondino, A. Morris, Z.S. Pitroda, S. Quezada, S.A. Santambrogio, L. Shiao, S. Stagg, J. Telarovic, I. Timmerman, R. Vozenin, M.-. Weichselbaum, R. Welsh, J. Wilkins, A. Xu, C. Zappasodi, R. Zou, W. Bobard, A. Demaria, S. Galluzzi, L. Deutsch, E. Formenti, S.C. (2023). Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. , Vol.12 (1), p. 2222560.  show abstract

Bozhanova, G. Hassan, J. Appleton, L. Jennings, V. Foo, S. McLaughlin, M. Chan Wah Hak, C.M. Patin, E.C. Crespo-Rodriguez, E. Baker, G. Armstrong, E. Chiu, M. Pandha, H. Samson, A. Roulstone, V. Kyula, J. Vile, R. Errington-Mais, F. Pedersen, M. Harrington, K. Ono, M. Melcher, A. (2022). CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. Journal for immunotherapy of cancer, Vol.10 (3), pp. e004410-?.  show abstract

Schuelke, M.R. Gundelach, J.H. Coffey, M. West, E. Scott, K. Johnson, D.R. Samson, A. Melcher, A. Vile, R.G. Bram, R.J. (2022). Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. , Vol.4 (1), p. vdac085.  show abstract

Patin, E.C. Dillon, M.T. Nenclares, P. Grove, L. Soliman, H. Leslie, I. Northcote, D. Bozhanova, G. Crespo-Rodriguez, E. Baldock, H. Whittock, H. Baker, G. Kyula, J. Guevara, J. Melcher, A.A. Harper, J. Ghadially, H. Smith, S. Pedersen, M. McLaughlin, M. Harrington, K.J. (2022). Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. Journal for immunotherapy of cancer, Vol.10 (3).  show abstract

Korlimarla, A. Ps, H. Prabhu, J. Ragulan, C. Patil, Y. Vp, S. Desai, K. Mathews, A. Appachu, S. Diwakar, R.B. Bs, S. Melcher, A. Cheang, M. Sadanandam, A. (2022). Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. , Vol.25, p. 101511.  show abstract

Wilkins, A. Hall, E. Lewis, R. Gribble, H. Melcher, A. Huddart, R. RE-ARM Trial Management Group,, (2022). RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy. Clinical oncology, .

Murray, J. Cruickshank, C. Bird, T. Bell, P. Braun, J. Chuter, D. Ferreira, M.R. Griffin, C. Hassan, S. Hujairi, N. Melcher, A. Miles, E. Naismith, O. Panades, M. Philipps, L. Reid, A. Rekowski, J. Sankey, P. Staffurth, J. Syndikus, I. Tree, A. Wilkins, A. Hall, E. PEARLS Trial Management Group,, (2022). PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation. , Vol.37, pp. 130-136.  show abstract

Samson, A. West, E.J. Carmichael, J. Scott, K.J. Turnbull, S. Kuszlewicz, B. Dave, R.V. Peckham-Cooper, A. Tidswell, E. Kingston, J. Johnpulle, M. da Silva, B. Jennings, V.A. Bendjama, K. Stojkowitz, N. Lusky, M. Prasad, K.R. Toogood, G.J. Auer, R. Bell, J. Twelves, C.J. Harrington, K.J. Vile, R.G. Pandha, H. Errington-Mais, F. Ralph, C. Newton, D.J. Anthoney, A. Melcher, A.A. Collinson, F. (2022). Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer immunology research, .  show abstract

Evgin, L. Kottke, T. Tonne, J. Thompson, J. Huff, A.L. van Vloten, J. Moore, M. Michael, J. Driscoll, C. Pulido, J. Swanson, E. Kennedy, R. Coffey, M. Loghmani, H. Sanchez-Perez, L. Olivier, G. Harrington, K. Pandha, H. Melcher, A. Diaz, R.M. Vile, R.G. (2022). Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Science translational medicine, Vol.14 (640).  show abstract

Gazinska, P. Milton, C. Iacovacci, J. Ward, J. Buus, R. Alaguthurai, T. Graham, R. Akarca, A. Lips, E. Naidoo, K. Wesseling, J. Marafioti, T. Cheang, M. Gillett, C. Wu, Y. Khan, A. Melcher, A. Salgado, R. Dowsett, M. Tutt, A. Roxanis, I. Haider, S. Irshad, S. (2022). Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers. , , pp. OF1-OF15.  show abstract

West, E.J. Scott, K.J. Tidswell, E. Bendjama, K. Stojkowitz, N. Lusky, M. Kurzawa, M. Prasad, R. Toogood, G. Ralph, C. Anthoney, D.A. Melcher, A.A. Collinson, F.J. Samson, A. (2022). Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. , Vol.14 (9), p. 2181.  show abstract

Melake, M.J. Smith, H.G. Mansfield, D. Davies, E. Dillon, M.T. Wilkins, A.C. Patin, E.C. Pedersen, M. Buus, R. Melcher, A.A. Thway, K. Miah, A.B. Zaidi, S.H. Hayes, A.J. Fenton, T.R. Harrington, K.J. McLaughlin, M. (2022). OX40 and 4-1BB delineate distinct immune profiles in sarcoma. , Vol.11 (1), p. 2066050.  show abstract

Andreou, T. Williams, J. Brownlie, R.J. Salmond, R.J. Watson, E. Shaw, G. Melcher, A. Wurdak, H. Short, S.C. Lorger, M. (2021). Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model. Journal for immunotherapy of cancer, Vol.9 (3).  show abstract

Müller, L.M. Migneco, G. Scott, G.B. Down, J. King, S. Askar, B. Jennings, V. Oyajobi, B. Scott, K. West, E. Ralph, C. Samson, A. Ilett, E.J. Muthana, M. Coffey, M. Melcher, A. Parrish, C. Cook, G. Lawson, M. Errington-Mais, F. (2021). Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for immunotherapy of cancer, Vol.9 (3).  show abstract

Roulstone, V. Mansfield, D. Harris, R.J. Twigger, K. White, C. de Bono, J. Spicer, J. Karagiannis, S.N. Vile, R. Pandha, H. Melcher, A. Harrington, K. (2021). Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. Journal for immunotherapy of cancer, Vol.9 (7).  show abstract

Wilkins, A. Fontana, E. Nyamundanda, G. Ragulan, C. Patil, Y. Mansfield, D. Kingston, J. Errington-Mais, F. Bottomley, D. von Loga, K. Bye, H. Carter, P. Tinkler-Hundal, E. Noshirwani, A. Downs, J. Dillon, M. Demaria, S. Sebag-Montefiore, D. Harrington, K. West, N. Melcher, A. Sadanandam, A. (2021). Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. J immunother cancer, Vol.9 (3).  show abstract

Challoner, B.R. von Loga, K. Woolston, A. Griffiths, B. Sivamanoharan, N. Semiannikova, M. Newey, A. Barber, L.J. Mansfield, D. Hewitt, L.C. Saito, Y. Davarzani, N. Starling, N. Melcher, A. Grabsch, H.I. Gerlinger, M. (2021). Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. Journal of the national cancer institute, Vol.113 (1), pp. 88-98.  show abstract

Vile, R.G. Melcher, A. Pandha, H. Harrington, K.J. Pulido, J.S. (2021). APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable. Clinical cancer research : an official journal of the american association for cancer research, .  show abstract

Appleton, E. Hassan, J. Chan Wah Hak, C. Sivamanoharan, N. Wilkins, A. Samson, A. Ono, M. Harrington, K.J. Melcher, A. Wennerberg, E. (2021). Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. , Vol.12, p. 754436.  show abstract

Kottke, T. Tonne, J. Evgin, L. Driscoll, C.B. van Vloten, J. Jennings, V.A. Huff, A.L. Zell, B. Thompson, J.M. Wongthida, P. Pulido, J. Schuelke, M.R. Samson, A. Selby, P. Ilett, E. McNiven, M. Roberts, L.R. Borad, M.J. Pandha, H. Harrington, K. Melcher, A. Vile, R.G. (2021). Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nature communications, Vol.12 (1), pp. 1930-?.  show abstract

Annels, N.E. Simpson, G.R. Denyer, M. Arif, M. Coffey, M. Melcher, A. Harrington, K. Vile, R. Pandha, H. (2021). Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors. Molecular therapy oncolytics, Vol.20, pp. 434-446.  show abstract

Crespo-Rodriguez, E. Bergerhoff, K. Bozhanova, G. Foo, S. Patin, E.C. Whittock, H. Buus, R. Haider, S. Muirhead, G. Thway, K. Newbold, K. Coffin, R.S. Vile, R.G. Kim, D. McLaughlin, M. Melcher, A.A. Harrington, K.J. Pedersen, M. (2020). Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Journal for immunotherapy of cancer, Vol.8 (2).  show abstract

Nenclares, P. Bhide, S.A. Sandoval-Insausti, H. Pialat, P. Gunn, L. Melcher, A. Newbold, K. Nutting, C.M. Harrington, K.J. (2020). Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. European journal of cancer (oxford, england : 1990), Vol.131, pp. 9-15.  show abstract

McLaughlin, M. Patin, E.C. Pedersen, M. Wilkins, A. Dillon, M.T. Melcher, A.A. Harrington, K.J. (2020). Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nature reviews. cancer, Vol.20 (4), pp. 203-217.  show abstract

Galluzzi, L. Vitale, I. Warren, S. Adjemian, S. Agostinis, P. Martinez, A.B. Chan, T.A. Coukos, G. Demaria, S. Deutsch, E. Draganov, D. Edelson, R.L. Formenti, S.C. Fucikova, J. Gabriele, L. Gaipl, U.S. Gameiro, S.R. Garg, A.D. Golden, E. Han, J. Harrington, K.J. Hemminki, A. Hodge, J.W. Hossain, D.M. Illidge, T. Karin, M. Kaufman, H.L. Kepp, O. Kroemer, G. Lasarte, J.J. Loi, S. Lotze, M.T. Manic, G. Merghoub, T. Melcher, A.A. Mossman, K.L. Prosper, F. Rekdal, Ø. Rescigno, M. Riganti, C. Sistigu, A. Smyth, M.J. Spisek, R. Stagg, J. Strauss, B.E. Tang, D. Tatsuno, K. van Gool, S.W. Vandenabeele, P. Yamazaki, T. Zamarin, D. Zitvogel, L. Cesano, A. Marincola, F.M. (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for immunotherapy of cancer, Vol.8 (1).  show abstract

Arwert, E.N. Milford, E.L. Rullan, A. Derzsi, S. Hooper, S. Kato, T. Mansfield, D. Melcher, A. Harrington, K.J. Sahai, E. (2020). STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy. Nature cell biology, Vol.22 (7), pp. 758-766.

Chiu, M. Armstrong, E.J. Jennings, V. Foo, S. Crespo-Rodriguez, E. Bozhanova, G. Patin, E.C. McLaughlin, M. Mansfield, D. Baker, G. Grove, L. Pedersen, M. Kyula, J. Roulstone, V. Wilkins, A. McDonald, F. Harrington, K. Melcher, A. (2020). Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert opinion on biological therapy, Vol.20 (6), pp. 635-652.  show abstract

Young, K. Lawlor, R.T. Ragulan, C. Patil, Y. Mafficini, A. Bersani, S. Antonello, D. Mansfield, D. Cingarlini, S. Landoni, L. Pea, A. Luchini, C. Piredda, L. Kannan, N. Nyamundanda, G. Morganstein, D. Chau, I. Wiedenmann, B. Milella, M. Melcher, A. Cunningham, D. Starling, N. Scarpa, A. Sadanandam, A. (2020). Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, .  show abstract

Driscoll, C.B. Schuelke, M.R. Kottke, T. Thompson, J.M. Wongthida, P. Tonne, J.M. Huff, A.L. Miller, A. Shim, K.G. Molan, A. Wetmore, C. Selby, P. Samson, A. Harrington, K. Pandha, H. Melcher, A. Pulido, J.S. Harris, R. Evgin, L. Vile, R.G. (2020). APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature communications, Vol.11 (1), pp. 790-?.  show abstract

Smith, H.G. Jamal, K. Dayal, J.H. Tenev, T. Kyula-Currie, J. Guppy, N. Gazinska, P. Roulstone, V. Liccardi, G. Davies, E. Roxanis, I. Melcher, A.A. Hayes, A.J. Inman, G.J. Harrington, K.J. Meier, P. (2020). RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. Embo molecular medicine, Vol.12 (6), pp. e10979-?.  show abstract

Punta, M. Jennings, V.A. Melcher, A.A. Lise, S. (2020). The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study. Frontiers in immunology, Vol.11, pp. 524968-?.  show abstract

Sadanandam, A. Bopp, T. Dixit, S. Knapp, D.J. Emperumal, C.P. Vergidis, P. Rajalingam, K. Melcher, A. Kannan, N. (2020). A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell death discovery, Vol.6 (1), pp. 141-?.  show abstract

Close, H.J. Stead, L.F. Nsengimana, J. Reilly, K.A. Droop, A. Wurdak, H. Mathew, R.K. Corns, R. Newton-Bishop, J. Melcher, A.A. Short, S.C. Cook, G.P. Wilson, E.B. (2020). Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clinical and experimental immunology, Vol.200 (1), pp. 33-44.  show abstract

McLaughlin, M. Pedersen, M. Roulstone, V. Bergerhoff, K.F. Smith, H.G. Whittock, H. Kyula, J.N. Dillon, M.T. Pandha, H.S. Vile, R. Melcher, A.A. Harrington, K.J. (2020). The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism. Molecular therapy oncolytics, Vol.16, pp. 238-249.  show abstract

Wilkins, A.C. Patin, E.C. Harrington, K.J. Melcher, A.A. (2019). The immunological consequences of radiation-induced DNA damage. The journal of pathology, Vol.247 (5), pp. 606-614.  show abstract

Smith, H.G. Mansfield, D. Roulstone, V. Kyula-Currie, J.N. McLaughlin, M. Patel, R.R. Bergerhoff, K.F. Paget, J.T. Dillon, M.T. Khan, A. Melcher, A. Thway, K. Harrington, K.J. Hayes, A.J. (2019). PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. Clinical cancer research : an official journal of the american association for cancer research, Vol.25 (11), pp. 3443-3454.  show abstract

Annels, N.E. Mansfield, D. Arif, M. Ballesteros-Merino, C. Simpson, G.R. Denyer, M. Sandhu, S.S. Melcher, A.A. Harrington, K.J. Davies, B. Au, G. Grose, M. Bagwan, I. Fox, B. Vile, R. Mostafid, H. Shafren, D. Pandha, H.S. (2019). Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the american association for cancer research, Vol.25 (19), pp. 5818-5831.  show abstract

Müller, L.M. Holmes, M. Michael, J.L. Scott, G.B. West, E.J. Scott, K.J. Parrish, C. Hall, K. Stäble, S. Jennings, V.A. Cullen, M. McConnell, S. Langton, C. Tidswell, E.L. Shafren, D. Samson, A. Harrington, K.J. Pandha, H. Ralph, C. Kelly, R.J. Cook, G. Melcher, A.A. Errington-Mais, F. (2019). Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for immunotherapy of cancer, Vol.7 (1), pp. 164-?.  show abstract

Evgin, L. Huff, A.L. Kottke, T. Thompson, J. Molan, A.M. Driscoll, C.B. Schuelke, M. Shim, K.G. Wongthida, P. Ilett, E.J. Smith, K.K. Harris, R.S. Coffey, M. Pulido, J.S. Pandha, H. Selby, P.J. Harrington, K.J. Melcher, A. Vile, R.G. (2019). Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer immunology research, Vol.7 (5), pp. 828-840.  show abstract

Dillon, M.T. Bergerhoff, K.F. Pedersen, M. Whittock, H. Crespo-Rodriguez, E. Patin, E.C. Pearson, A. Smith, H.G. Paget, J.T. Patel, R.R. Foo, S. Bozhanova, G. Ragulan, C. Fontana, E. Desai, K. Wilkins, A.C. Sadanandam, A. Melcher, A. McLaughlin, M. Harrington, K.J. (2019). ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clinical cancer research : an official journal of the american association for cancer research, Vol.25 (11), pp. 3392-3403.  show abstract

Jennings, V.A. Scott, G.B. Rose, A.M. Scott, K.J. Migneco, G. Keller, B. Reilly, K. Donnelly, O. Peach, H. Dewar, D. Harrington, K.J. Pandha, H. Samson, A. Vile, R.G. Melcher, A.A. Errington-Mais, F. (2019). Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular therapy : the journal of the american society of gene therapy, Vol.27 (6), pp. 1139-1152.  show abstract

Wilkins, A. McDonald, F. Harrington, K. Melcher, A. (2019). Radiotherapy enhances responses of lung cancer to CTLA-4 blockade. Journal for immunotherapy of cancer, Vol.7 (1), pp. 64-?.  show abstract

Gonzalez-Exposito, R. Semiannikova, M. Griffiths, B. Khan, K. Barber, L.J. Woolston, A. Spain, G. von Loga, K. Challoner, B. Patel, R. Ranes, M. Swain, A. Thomas, J. Bryant, A. Saffery, C. Fotiadis, N. Guettler, S. Mansfield, D. Melcher, A. Powles, T. Rao, S. Watkins, D. Chau, I. Matthews, N. Wallberg, F. Starling, N. Cunningham, D. Gerlinger, M. (2019). CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. Journal for immunotherapy of cancer, Vol.7 (1), pp. 101-?.  show abstract

Samson, A. Bentham, M.J. Scott, K. Nuovo, G. Bloy, A. Appleton, E. Adair, R.A. Dave, R. Peckham-Cooper, A. Toogood, G. Nagamori, S. Coffey, M. Vile, R. Harrington, K. Selby, P. Errington-Mais, F. Melcher, A. Griffin, S. (2018). Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, Vol.67 (3), pp. 562-573.  show abstract

Comins, C. Simpson, G.R. Rogers, W. Relph, K. Harrington, K. Melcher, A. Roulstone, V. Kyula, J. Pandha, H. (2018). Synergistic antitumour effects of rapamycin and oncolytic reovirus. Cancer gene therapy, Vol.25 (5-6), pp. 148-160.  show abstract

Wilkins, A. Melcher, A. Somaiah, N. (2018). Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. Clinical oncology (royal college of radiologists (great britain)), Vol.30 (10), pp. 605-608.

Berkeley, R.A. Steele, L.P. Mulder, A.A. van den Wollenberg, D.J. Kottke, T.J. Thompson, J. Coffey, M. Hoeben, R.C. Vile, R.G. Melcher, A. Ilett, E.J. (2018). Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer immunology research, Vol.6 (10), pp. 1161-1173.  show abstract

Samson, A. Scott, K.J. Taggart, D. West, E.J. Wilson, E. Nuovo, G.J. Thomson, S. Corns, R. Mathew, R.K. Fuller, M.J. Kottke, T.J. Thompson, J.M. Ilett, E.J. Cockle, J.V. van Hille, P. Sivakumar, G. Polson, E.S. Turnbull, S.J. Appleton, E.S. Migneco, G. Rose, A.S. Coffey, M.C. Beirne, D.A. Collinson, F.J. Ralph, C. Alan Anthoney, D. Twelves, C.J. Furness, A.J. Quezada, S.A. Wurdak, H. Errington-Mais, F. Pandha, H. Harrington, K.J. Selby, P.J. Vile, R.G. Griffin, S.D. Stead, L.F. Short, S.C. Melcher, A.A. (2018). Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science translational medicine, Vol.10 (422).  show abstract

Taggart, D. Andreou, T. Scott, K.J. Williams, J. Rippaus, N. Brownlie, R.J. Ilett, E.J. Salmond, R.J. Melcher, A. Lorger, M. (2018). Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc natl acad sci u s a, Vol.115 (7), pp. E1540-E1549.  show abstract

Huff, A.L. Wongthida, P. Kottke, T. Thompson, J.M. Driscoll, C.B. Schuelke, M. Shim, K.G. Harris, R.S. Molan, A. Pulido, J.S. Selby, P.J. Harrington, K.J. Melcher, A. Evgin, L. Vile, R.G. (2018). APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular therapy oncolytics, Vol.11, pp. 1-13.  show abstract

Khan, A.A. Paget, J.T. McLaughlin, M. Kyula, J.N. Wilkinson, M.J. Pencavel, T. Mansfield, D. Roulstone, V. Seth, R. Halle, M. Somaiah, N. Boult, J.K. Robinson, S.P. Pandha, H.S. Vile, R.G. Melcher, A.A. Harris, P.A. Harrington, K.J. (2018). Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. Science translational medicine, Vol.10 (425).  show abstract

Annels, N.E. Arif, M. Simpson, G.R. Denyer, M. Moller-Levet, C. Mansfield, D. Butler, R. Shafren, D. Au, G. Knowles, M. Harrington, K. Vile, R. Melcher, A. Pandha, H. (2018). Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Molecular therapy oncolytics, Vol.9, pp. 1-12.  show abstract

Ilett, E. Kottke, T. Thompson, J. Rajani, K. Zaidi, S. Evgin, L. Coffey, M. Ralph, C. Diaz, R. Pandha, H. Harrington, K. Selby, P. Bram, R. Melcher, A. Vile, R. (2017). Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene therapy, Vol.24 (1), pp. 21-30.  show abstract

Kottke, T. Evgin, L. Shim, K.G. Rommelfanger, D. Boisgerault, N. Zaidi, S. Diaz, R.M. Thompson, J. Ilett, E. Coffey, M. Selby, P. Pandha, H. Harrington, K. Melcher, A. Vile, R. (2017). Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. Cancer immunology research, Vol.5 (11), pp. 1029-1045.  show abstract

Cockle, J.V. Brüning-Richardson, A. Scott, K.J. Thompson, J. Kottke, T. Morrison, E. Ismail, A. Carcaboso, A.M. Rose, A. Selby, P. Conner, J. Picton, S. Short, S. Vile, R. Melcher, A. Ilett, E. (2017). Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular therapy oncolytics, Vol.5, pp. 75-86.  show abstract

Rajani, K. Parrish, C. Kottke, T. Thompson, J. Zaidi, S. Ilett, L. Shim, K.G. Diaz, R.-. Pandha, H. Harrington, K. Coffey, M. Melcher, A. Vile, R. (2016). Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Molecular therapy : the journal of the american society of gene therapy, Vol.24 (1), pp. 166-174.  show abstract

Mansfield, D.C. Kyula, J.N. Rosenfelder, N. Chao-Chu, J. Kramer-Marek, G. Khan, A.A. Roulstone, V. McLaughlin, M. Melcher, A.A. Vile, R.G. Pandha, H.S. Khoo, V. Harrington, K.J. (2016). Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene therapy, Vol.23 (4), pp. 357-368.  show abstract

Cockle, J.V. Rajani, K. Zaidi, S. Kottke, T. Thompson, J. Diaz, R.M. Shim, K. Peterson, T. Parney, I.F. Short, S. Selby, P. Ilett, E. Melcher, A. Vile, R. (2016). Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-oncology, Vol.18 (4), pp. 518-527.

Kottke, T. Shim, K.G. Alonso-Camino, V. Zaidi, S. Maria Diaz, R. Pulido, J. Thompson, J. Rajani, K.R. Evgin, L. Ilett, E. Pandha, H. Harrington, K. Selby, P. Melcher, A. Vile, R. (2016). Immunogenicity of self tumor associated proteins is enhanced through protein truncation. Molecular therapy oncolytics, Vol.3, pp. 16030-?.  show abstract

Holyoake, D.L. Ward, E. Grose, D. McIntosh, D. Sebag-Montefiore, D. Radhakrishna, G. Patel, N. Silva, M. Mukherjee, S. Strauss, V.Y. Odondi, L. Fokas, E. Melcher, A. Hawkins, M.A. (2016). A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Bmc cancer, Vol.16 (1), pp. 728-?.  show abstract

Roulstone, V. Pedersen, M. Kyula, J. Mansfield, D. Khan, A.A. McEntee, G. Wilkinson, M. Karapanagiotou, E. Coffey, M. Marais, R. Jebar, A. Errington-Mais, F. Melcher, A. Vile, R. Pandha, H. McLaughlin, M. Harrington, K.J. (2015). BRAF- and MEK-targeted Small Molecule Inhibitors Exert Enhanced Anti-Melanoma Effects in Combination with Oncolytic Reovirus through ER Stress. Molecular therapy : the journal of the american society of gene therapy, Vol.23, pp. 931-942.  show abstract

Jebar, A.H. Vile, R.G. Melcher, A.A. Griffin, S. Selby, P.J. Errington-Mais, F. (2015). Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of general virology, Vol.96 (7), pp. 1533-1550.

Seth, R. Khan, A.A. Pencavel, T.D. Wilkinson, M.J. Kyula, J.N. Simpson, G. Pandha, H. Melcher, A. Vile, R. Harris, P.A. Harrington, K.J. (2015). Adenovirally Delivered Enzyme Prodrug Therapy with Herpes Simplex Virus–Thymidine Kinase in Composite Tissue Free Flaps Shows Therapeutic Efficacy in Rat Models of Glioma. Plastic and reconstructive surgery, Vol.135, pp. 475-487.

Cockle, J.V. Picton, S. Levesley, J. Ilett, E. Carcaboso, A.M. Short, S. Steel, L.P. Melcher, A. Lawler, S.E. Brüning-Richardson, A. (2015). Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. British journal of cancer, Vol.112 (4), pp. 693-703.

Appleton, E.S. Turnbull, S. Ralph, C. West, E. Scott, K. Harrington, K. Pandha, H. Melcher, A. (2015). Talimogene laherparepvec in the treatment of melanoma. Expert opinion on biological therapy, Vol.15 (10), pp. 1517-1530.

Zaidi, S. Blanchard, M. Shim, K. Ilett, E. Rajani, K. Parrish, C. Boisgerault, N. Kottke, T. Thompson, J. Celis, E. Pulido, J. Selby, P. Pandha, H. Melcher, A. Harrington, K. Vile, R. (2015). Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Molecular therapy, Vol.23 (5), pp. 845-856.

Parrish, C. Scott, G.B. Migneco, G. Scott, K.J. Steele, L.P. Ilett, E. West, E.J. Hall, K. Selby, P.J. Buchanan, D. Varghese, A. Cragg, M.S. Coffey, M. Hillmen, P. Melcher, A.A. Errington-Mais, F. (2015). Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, Vol.29 (9), pp. 1799-1810.

El-Sherbiny, Y.M. Holmes, T.D. Wetherill, L.F. Black, E.V. Wilson, E.B. Phillips, S.L. Scott, G.B. Adair, R.A. Dave, R. Scott, K.J. Morgan, R.S. Coffey, M. Toogood, G.J. Melcher, A.A. Cook, G.P. (2015). Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cellsin vivo. Clinical and experimental immunology, Vol.180 (1), pp. 98-107.  show abstract

Blanchard, M. Shim, K.G. Grams, M.P. Rajani, K. Diaz, R.M. Furutani, K.M. Thompson, J. Olivier, K.R. Park, S.S. Markovic, S.N. Pandha, H. Melcher, A. Harrington, K. Zaidi, S. Vile, R. (2015). Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. International journal of radiation oncology*biology*physics, Vol.93 (3), pp. 577-587.

Roulstone, V. Khan, K. Pandha, H.S. Rudman, S. Coffey, M. Gill, G.M. Melcher, A.A. Vile, R. Harrington, K.J. de Bono, J. Spicer, J. (2015). Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical cancer research, Vol.21 (6), pp. 1305-1312.  show abstract

Jennings, V.A. Ilett, E.J. Scott, K.J. West, E.J. Vile, R. Pandha, H. Harrington, K. Young, A. Hall, G.D. Coffey, M. Selby, P. Errington‐Mais, F. Melcher, A.A. (2014). Lymphokine‐activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. International journal of cancer, Vol.134 (5), pp. 1091-1101.  show abstract

Alonso-Camino, V. Rajani, K. Kottke, T. Rommelfanger-Konkol, D. Zaidi, S. Thompson, J. Pulido, J. Ilett, L. Selby, P. Pandha, H. Melcher, A. Harrington, K. Diaz, R. Vile, R. (2014). The Profile of Tumor Antigens Which Can Be Targeted By Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular therapy, Vol.22, pp. S200-S200.

Ilett, E. Kottke, T. Donnelly, O. Thompson, J. Willmon, C. Diaz, R. Zaidi, S. Coffey, M. Selby, P. Harrington, K. Pandha, H. Melcher, A. Vile, R. (2014). Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. Molecular therapy, Vol.22 (10), pp. 1851-1863.

Alonso-Camino, V. Rajani, K. Kottke, T. Rommelfanger-Konkol, D. Zaidi, S. Thompson, J. Pulido, J. Ilett, E. Donnelly, O. Selby, P. Pandha, H. Melcher, A. Harrington, K. Diaz, R.M. Vile, R. (2014). The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular therapy, Vol.22 (11), pp. 1936-1948.

Kyula, J.N. Khan, A.A. Mansfield, D. Karapanagiotou, E.M. McLaughlin, M. Roulstone, V. Zaidi, S. Pencavel, T. Touchefeu, Y. Seth, R. Chen, N.G. Yu, Y.A. Zhang, Q. Melcher, A.A. Vile, R.G. Pandha, H.S. Ajaz, M. Szalay, A.A. Harrington, K.J. (2014). Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, Vol.33 (13), pp. 1700-1712.  show abstract

Donnelly, O.G. Errington-Mais, F. Steele, L. Hadac, E. Jennings, V. Scott, K. Peach, H. Phillips, R.M. Bond, J. Pandha, H. Harrington, K. Vile, R. Russell, S. Selby, P. Melcher, A.A. (2013). Measles virus causes immunogenic cell death in human melanoma. Gene therapy, Vol.20 (1), pp. 7-15.

Mansfield, D. Pencavel, T. Kyula, J.N. Zaidi, S. Roulstone, V. Thway, K. Karapanagiotou, L. Khan, A.A. McLaughlin, M. Touchefeu, Y. Seth, R. Melcher, A.A. Vile, R.G. Pandha, H.S. Harrington, K.J. (2013). Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral oncology, Vol.49, pp. 108-118.  show abstract

Roulstone, V. Twigger, K. Zaidi, S. Pencavel, T. Kyula, J.N. White, C. McLaughlin, M. Seth, R. Karapanagiotou, E.M. Mansfield, D. Coffey, M. Nuovo, G. Vile, R.G. Pandha, H.S. Melcher, A.A. Harrington, K.J. (2013). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy. Gene therapy, Vol.20 (5), pp. 521-528.

Cockle, J.V. Picton, S.V. Melcher, A. (2013). Future clinical potential of oncolytic virotherapy for pediatric CNS tumors. Cns oncology, Vol.2 (4), pp. 307-310.

Donnelly, O. Harrington, K. Melcher, A. Pandha, H. (2013). Live viruses to treat cancer. Journal of the royal society of medicine, Vol.106 (8), pp. 310-314.  show abstract

Boisgerault, N. Kottke, T. Pulido, J. Thompson, J. Diaz, R.M. Rommelfanger-Konkol, D. Embry, A. Saenz, D. Poeschla, E. Pandha, H. Harrington, K. Melcher, A. Selby, P. Vile, R. (2013). Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse. Molecular therapy, Vol.21 (8), pp. 1507-1516.

Kottke, T. Boisgerault, N. Diaz, R.M. Donnelly, O. Rommelfanger-Konkol, D. Pulido, J. Thompson, J. Mukhopadhyay, D. Kaspar, R. Coffey, M. Pandha, H. Melcher, A. Harrington, K. Selby, P. Vile, R. (2013). Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature medicine, Vol.19 (12), pp. 1625-1631.

Adair, R.A. Scott, K.J. Fraser, S. Errington‐Mais, F. Pandha, H. Coffey, M. Selby, P. Cook, G.P. Vile, R. Harrington, K.J. Toogood, G. Melcher, A.A. (2013). Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cells. International journal of cancer, Vol.132 (10), pp. 2327-2338.  show abstract

Tai, L.-. Zhang, J. Scott, K.J. de Souza, C.T. Alkayyal, A.A. Ananth, A.A. Sahi, S. Adair, R.A. Mahmoud, A.B. Sad, S. Bell, J.C. Makrigiannis, A.P. Melcher, A.A. Auer, R.C. (2013). Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells. Clinical cancer research, Vol.19 (18), pp. 5104-5115.  show abstract

Karapanagiotou, E.M. Roulstone, V. Twigger, K. Ball, M. Tanay, M. Nutting, C. Newbold, K. Gore, M.E. Larkin, J. Syrigos, K.N. Coffey, M. Thompson, B. Mettinger, K. Vile, R.G. Pandha, H.S. Hall, G.D. Melcher, A.A. Chester, J. Harrington, K.J. (2012). Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Clinical cancer research, Vol.18 (7), pp. 2080-2089.  show abstract

Simpson, G.R. Horvath, A. Annels, N.E. Pencavel, T. Metcalf, S. Seth, R. Peschard, P. Price, T. Coffin, R.S. Mostafid, H. Melcher, A.A. Harrington, K.J. Pandha, H.S. (2012). Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British journal of cancer, Vol.106 (3), pp. 496-507.

G. Donnelly, O. Errington-Mais, F. Prestwich, R. Harrington, K. Pandha, H. Vile, R. A. Melcher, A. (2012). Recent Clinical Experience with Oncolytic Viruses. Current pharmaceutical biotechnology, Vol.13 (9), pp. 1834-1841.

Kyula, J.N. Roulstone, V. Karapanagiotou, E.M. Melcher, A.A. Harrington, K.J. (2012). Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert opinion on biological therapy, Vol.12 (12), pp. 1669-1678.  show abstract

Nuovo, G.J. Garofalo, M. Valeri, N. Roulstone, V. Volinia, S. Cohn, D.E. Phelps, M. Harrington, K.J. Vile, R. Melcher, A. Galanis, E. Sehl, S. Adair, R. Scott, K. Rose, A. Toogood, G. Coffey, M.C. (2012). Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern pathology, Vol.25 (10), pp. 1333-1344.

Twigger, K. Roulstone, V. Kyula, J. Karapanagiotou, E.M. Syrigos, K.N. Morgan, R. White, C. Bhide, S. Nuovo, G. Coffey, M. Thompson, B. Jebar, A. Errington, F. Melcher, A.A. Vile, R.G. Pandha, H.S. Harrington, K.J. (2012). Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. Bmc cancer, Vol.12 (1).  show abstract

Adair, R.A. Roulstone, V. Scott, K.J. Morgan, R. Nuovo, G.J. Fuller, M. Beirne, D. West, E.J. Jennings, V.A. Rose, A. Kyula, J. Fraser, S. Dave, R. Anthoney, D.A. Merrick, A. Prestwich, R. Aldouri, A. Donnelly, O. Pandha, H. Coffey, M. Selby, P. Vile, R. Toogood, G. Harrington, K. Melcher, A.A. (2012). Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients. Science translational medicine, Vol.4 (138).  show abstract

Pulido, J. Kottke, T. Thompson, J. Galivo, F. Wongthida, P. Diaz, R.M. Rommelfanger, D. Ilett, E. Pease, L. Pandha, H. Harrington, K. Selby, P. Melcher, A. Vile, R. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature biotechnology, Vol.30 (4), pp. 337-343.  show abstract

Donnelly, O. Vile, R. Pandha, H. Harrington, K. Melcher, A. (2012). The Hitchhiker's Guide to Virotherapy. Oncotarget, Vol.3 (8), pp. 735-736.

Ilett, E.J. Bárcena, M. Errington-Mais, F. Griffin, S. Harrington, K.J. Pandha, H.S. Coffey, M. Selby, P.J. Limpens, R.W. Mommaas, M. Hoeben, R.C. Vile, R.G. Melcher, A.A. (2011). Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from Neutralization. Clinical cancer research, Vol.17 (9), pp. 2767-2776.  show abstract

Willmon, C. Diaz, R.M. Wongthida, P. Galivo, F. Kottke, T. Thompson, J. Albelda, S. Harrington, K. Melcher, A. Vile, R. (2011). Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. Molecular therapy, Vol.19 (1), pp. 140-149.

Kottke, T. Errington, F. Pulido, J. Galivo, F. Thompson, J. Wongthida, P. Diaz, R.M. Chong, H. Ilett, E. Chester, J. Pandha, H. Harrington, K. Selby, P. Melcher, A. Vile, R. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature medicine, Vol.17 (7), pp. 854-859.

West, E.J. Scott, K.J. Jennings, V.A. Melcher, A.A. (2011). Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. British journal of cancer, Vol.105 (6), pp. 787-795.

Kottke, T. Chester, J. Ilett, E. Thompson, J. Diaz, R. Coffey, M. Selby, P. Nuovo, G. Pulido, J. Mukhopadhyay, D. Pandha, H. Harrington, K. Melcher, A. Vile, R. (2011). Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy. Molecular therapy, Vol.19 (10), pp. 1802-1812.

Heinemann, L. Simpson, G.R. Boxall, A. Kottke, T. Relph, K.L. Vile, R. Melcher, A. Prestwich, R. Harrington, K.J. Morgan, R. Pandha, H.S. (2011). Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. Bmc cancer, Vol.11 (1).  show abstract

Steele, L. Errington, F. Prestwich, R. Ilett, E. Harrington, K. Pandha, H. Coffey, M. Selby, P. Vile, R. Melcher, A. (2011). Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Molecular cancer, Vol.10 (1).  show abstract

Hingorani, M. Spitzweg, C. Vassaux, G. Newbold, K. Melcher, A. Pandha, H. Vile, R. Harrington, K. (2010). The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery. Current cancer drug targets, Vol.10 (2), pp. 242-267.

Harrington, K.J. Karapanagiotou, E.M. Roulstone, V. Twigger, K.R. White, C.L. Vidal, L. Beirne, D. Prestwich, R. Newbold, K. Ahmed, M. Thway, K. Nutting, C.M. Coffey, M. Harris, D. Vile, R.G. Pandha, H.S. DeBono, J.S. Melcher, A.A. (2010). Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clinical cancer research, Vol.16 (11), pp. 3067-3077.  show abstract

Kottke, T. Hall, G. Pulido, J. Diaz, R.M. Thompson, J. Chong, H. Selby, P. Coffey, M. Pandha, H. Chester, J. Melcher, A. Harrington, K. Vile, R. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. Journal of clinical investigation, Vol.120 (5), pp. 1551-1560.

Harrington, K.J. Vile, R.G. Melcher, A. Chester, J. Pandha, H.S. (2010). Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine & growth factor reviews, Vol.21 (2-3), pp. 91-98.

Pencavel, T. Seth, R. Hayes, A. Melcher, A. Pandha, H. Vile, R. Harrington, K.J. (2010). Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?. Gene therapy, Vol.17 (8), pp. 949-960.

Hingorani, M. White, C.L. Zaidi, S. Pandha, H.S. Melcher, A.A. Bhide, S.A. Nutting, C.M. Syrigos, K.N. Vile, R.G. Vassaux, G. Harrington, K.J. (2010). Therapeutic Effect of Sodium Iodide Symporter Gene Therapy Combined With External Beam Radiotherapy and Targeted Drugs That Inhibit DNA Repair. Molecular therapy, Vol.18 (9), pp. 1599-1605.

Heinemann, L. Simpson, G.R. Annels, N.E. Vile, R. Melcher, A. Prestwich, R. Harrington, K.J. Pandha, H.S. (2010). The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis. Molecular therapy, Vol.18 (12), pp. 2085-2093.

Comins, C. Spicer, J. Protheroe, A. Roulstone, V. Twigger, K. White, C.M. Vile, R. Melcher, A. Coffey, M.C. Mettinger, K.L. Nuovo, G. Cohn, D.E. Phelps, M. Harrington, K.J. Pandha, H.S. (2010). REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clinical cancer research, Vol.16 (22), pp. 5564-5572.  show abstract

Kottke, T. Pulido, J. Thompson, J. Sanchez-Perez, L. Chong, H. Calderwood, S.K. Selby, P. Harrington, K. Strome, S.E. Melcher, A. Vile, R.G. (2009). Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70–Mediated Inflammatory Killing of Normal Pancreas. Cancer research, Vol.69 (19), pp. 7767-7774.  show abstract

Pandha, H.S. Heinemann, L. Simpson, G.R. Melcher, A. Prestwich, R. Errington, F. Coffey, M. Harrington, K.J. Morgan, R. (2009). Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma. Clinical cancer research, Vol.15 (19), pp. 6158-6166.  show abstract

Agrawal, V.K. Copeland, K.M. Barbachano, Y. Rahim, A. Seth, R. White, C.L. Hingorani, M. Nutting, C.M. Kelly, M. Harris, P. Pandha, H. Melcher, A.A. Vile, R.G. Porter, C. Harrington, K.J. (2009). Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene therapy, Vol.16 (1), pp. 78-92.

Prestwich, R.J. Errington, F. Steele, L.P. Ilett, E.J. Morgan, R.S. Harrington, K.J. Pandha, H.S. Selby, P.J. Vile, R.G. Melcher, A.A. (2009). Reciprocal Human Dendritic Cell–Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus. The journal of immunology, Vol.183 (7), pp. 4312-4321.  show abstract

Prestwich, R.J. Ilett, E.J. Errington, F. Diaz, R.M. Steele, L.P. Kottke, T. Thompson, J. Galivo, F. Harrington, K.J. Pandha, H.S. Selby, P.J. Vile, R.G. Melcher, A.A. (2009). Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication. Clinical cancer research, Vol.15 (13), pp. 4374-4381.  show abstract

West, E. Morgan, R. Scott, K. Merrick, A. Lubenko, A. Pawson, D. Selby, P. Hatfield, P. Prestwich, R. Fraser, S. Eves, D. Anthoney, A. Twelves, C. Beirne, D. Patel, P. O'Donnell, D. Watt, S. Waller, M. Dietz, A. Robinson, P. Melcher, A. (2009). Clinical Grade OK432-activated Dendritic Cells. Journal of immunotherapy, Vol.32 (1), pp. 66-78.

Prestwich, R.J. Scott, K.J. Brown, J. Harnden, P. Whelan, P. Cartledge, J. O’Donnell, D. Pandha, H.S. Selby, P.J. Banks, R.E. Merrick, A.E. Melcher, A.A. (2009). The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. Bju international, Vol.103 (6), pp. 740-746.  show abstract

Ilett, E.J. Prestwich, R.J. Kottke, T. Errington, F. Thompson, J.M. Harrington, K.J. Pandha, H.S. Coffey, M. Selby, P.J. Vile, R.G. Melcher, A.A. (2009). Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene therapy, Vol.16 (5), pp. 689-699.

Willmon, C. Harrington, K. Kottke, T. Prestwich, R. Melcher, A. Vile, R. (2009). Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy. Molecular therapy, Vol.17 (10), pp. 1667-1676.

Prestwich, R.J. Errington, F. Diaz, R.M. Pandha, H.S. Harrington, K.J. Melcher, A.A. Vile, R.G. (2009). The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon. Human gene therapy, Vol.20 (10), pp. 1119-1132.

Kottke, T. Thompson, J. Diaz, R.M. Pulido, J. Willmon, C. Coffey, M. Selby, P. Melcher, A. Harrington, K. Vile, R.G. (2009). Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. Clinical cancer research, Vol.15 (2), pp. 561-569.  show abstract

Saunders, M. Anthoney, A. Coffey, M. Mettinger, K. Thompson, B. Melcher, A. Nutting, C.M. Harrington, K. (2009). Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J clin oncol, Vol.27 (15_suppl), p. e14514.  show abstract

Karapanagiotou, E. Pandha, H.S. Hall, G. Chester, J. Melcher, A. Coffey, M. de Bono, J. Gore, M.E. Nutting, C.M. Harrington, K.J. (2009). Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. J clin oncol, Vol.27 (15_suppl), p. e14519.  show abstract

Qiao, J. Wang, H. Kottke, T. White, C. Twigger, K. Diaz, R.M. Thompson, J. Selby, P. de Bono, J. Melcher, A. Pandha, H. Coffey, M. Vile, R. Harrington, K. (2008). Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Clinical cancer research, Vol.14 (1), pp. 259-269.  show abstract

Twigger, K. Vidal, L. White, C.L. De Bono, J.S. Bhide, S. Coffey, M. Thompson, B. Vile, R.G. Heinemann, L. Pandha, H.S. Errington, F. Melcher, A.A. Harrington, K.J. (2008). Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy. Clinical cancer research, Vol.14 (3), pp. 912-923.  show abstract

Qiao, J. Kottke, T. Willmon, C. Galivo, F. Wongthida, P. Diaz, R.M. Thompson, J. Ryno, P. Barber, G.N. Chester, J. Selby, P. Harrington, K. Melcher, A. Vile, R.G. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature medicine, Vol.14 (1), pp. 37-44.

Hingorani, M. White, C.L. Merron, A. Peerlinck, I. Gore, M.E. Slade, A. Scott, S.D. Nutting, C.M. Pandha, H.S. Melcher, A.A. Vile, R.G. Vassaux, G. Harrington, K.J. (2008). Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors. Cancer research, Vol.68 (23), pp. 9771-9778.  show abstract

Vidal, L. Pandha, H.S. Yap, T.A. White, C.L. Twigger, K. Vile, R.G. Melcher, A. Coffey, M. Harrington, K.J. DeBono, J.S. (2008). A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clinical cancer research, Vol.14 (21), pp. 7127-7137.  show abstract

Errington, F. Steele, L. Prestwich, R. Harrington, K.J. Pandha, H.S. Vidal, L. de Bono, J. Selby, P. Coffey, M. Vile, R. Melcher, A. (2008). Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity. The journal of immunology, Vol.180 (9), pp. 6018-6026.  show abstract

Hingorani, M. White, C.L. Zaidi, S. Merron, A. Peerlinck, I. Gore, M.E. Nutting, C.M. Pandha, H.S. Melcher, A.A. Vile, R.G. Vassaux, G. Harrington, K.J. (2008). Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy. Clinical cancer research, Vol.14 (15), pp. 4915-4924.  show abstract

Hill, K.S. Errington, F. Steele, L.P. Merrick, A. Morgan, R. Selby, P.J. Georgopoulos, N.T. O'Donnell, D.M. Melcher, A.A. (2008). OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions. The journal of immunology, Vol.181 (5), pp. 3108-3115.  show abstract

Prestwich, R.J. Errington, F. Harrington, K.J. Pandha, H.S. Selby, P. Melcher, A. (2008). Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?. Clinical medicine. oncology, Vol.2, pp. CMO.S416-CMO.S416.  show abstract

White, C.L. Menghistu, T. Twigger, K.R. Searle, P.F. Bhide, S.A. Vile, R.G. Melcher, A.A. Pandha, H.S. Harrington, K.J. (2008). Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene therapy, Vol.15 (6), pp. 424-433.

Prestwich, R.J. Errington, F. Hatfield, P. Merrick, A.E. Ilett, E.J. Selby, P.J. Melcher, A.A. (2008). The Immune System — is it Relevant to Cancer Development, Progression and Treatment?. Clinical oncology, Vol.20 (2), pp. 101-112.

White, C.L. Twigger, K.R. Vidal, L. De Bono, J.S. Coffey, M. Heinemann, L. Morgan, R. Merrick, A. Errington, F. Vile, R.G. Melcher, A.A. Pandha, H.S. Harrington, K.J. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene therapy, Vol.15 (12), pp. 911-920.

Merrick, A. Diaz, R.M. O’Donnell, D. Selby, P. Vile, R. Melcher, A. (2008). Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy. Cancer immunology, immunotherapy, Vol.57 (6), pp. 897-906.

Prestwich, R.J. Harrington, K.J. Vile, R.G. Melcher, A.A. (2008). Immunotherapeutic potential of oncolytic virotherapy. The lancet oncology, Vol.9 (7), pp. 610-612.

Kottke, T. Galivo, F. Wongthida, P. Maria Diaz, R. Thompson, J. Jevremovic, D. Barber, G.N. Hall, G. Chester, J. Selby, P. Harrington, K. Melcher, A. Vile, R.G. (2008). Treg Depletion–enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Molecular therapy, Vol.16 (7), pp. 1217-1226.

Harrington, K.J. Melcher, A. Vassaux, G. Pandha, H.S. Vile, R.G. (2008). Exploiting synergies between radiation and oncolytic viruses. Current opinion in molecular therapeutics, Vol.10 (4), pp. 362-370.

Comins, C. Heinemann, L. Harrington, K. Melcher, A. De Bono, J. Pandha, H. (2008). Reovirus: Viral Therapy for Cancer ‘as Nature Intended’. Clinical oncology, Vol.20 (7), pp. 548-554.

Errington, F. White, C.L. Twigger, K.R. Rose, A. Scott, K. Steele, L. Ilett, L.J. Prestwich, R. Pandha, H.S. Coffey, M. Selby, P. Vile, R. Harrington, K.J. Melcher, A.A. (2008). Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene therapy, Vol.15 (18), pp. 1257-1270.

Hatfield, P. Merrick, A.E. West, E. O'Donnell, D. Selby, P. Vile, R. Melcher, A.A. (2008). Optimization of Dendritic Cell Loading With Tumor Cell Lysates for Cancer Immunotherapy. Journal of immunotherapy, Vol.31 (7), pp. 620-632.

Prestwich, R.J. Harrington, K.J. Pandha, H.S. Vile, R.G. Melcher, A.A. Errington, F. (2008). Oncolytic viruses: a novel form of immunotherapy. Expert review of anticancer therapy, Vol.8 (10), pp. 1581-1588.

Kottke, T. Diaz, R.M. Kaluza, K. Pulido, J. Galivo, F. Wongthida, P. Thompson, J. Willmon, C. Barber, G.N. Chester, J. Selby, P. Strome, S. Harrington, K. Melcher, A. Vile, R.G. (2008). Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer. Molecular therapy, Vol.16 (12), pp. 1910-1918.

Prestwich, R.J. Errington, F. Ilett, E.J. Morgan, R.S. Scott, K.J. Kottke, T. Thompson, J. Morrison, E.E. Harrington, K.J. Pandha, H.S. Selby, P.J. Vile, R.G. Melcher, A.A. (2008). Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity. Clinical cancer research, Vol.14 (22), pp. 7358-7366.  show abstract

Hingorani, M. White, C. Agrawal, V. Vidal, L. Melcher, A. Harrington, K. (2007). Combining Radiation and Cancer Gene Therapy: A Potential Marriage of Physical and Biological Targeting?. Current cancer drug targets, Vol.7 (4), pp. 389-409.

Craven, I. Crellin, A. Cooper, R. Melcher, A. Byrne, P. Sebag-Montefiore, D. (2007). Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. British journal of cancer, Vol.97 (10), pp. 1333-1337.

Harris, D. Vidal, L. Melcher, A. Newbold, K. Anthony, A. Karavasilis, V. Agarwal, R. White, C. Twigger, K. Coffey, M. Mettinger, K. Thompson, B. Pandha, H. De-Bono, J. Harrington, K. (2007). A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies. Molecular cancer therapeutics, Vol.6 (12), pp. 3458S-3458S.

Kottke, T. Sanchez-Perez, L. Diaz, R.M. Thompson, J. Chong, H. Harrington, K. Calderwood, S.K. Pulido, J. Georgopoulos, N. Selby, P. Melcher, A. Vile, R. (2007). Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer. Cancer research, Vol.67 (24), pp. 11970-11979.  show abstract

Georgopoulos, N.T. Merrick, A. Scott, N. Selby, P.J. Melcher, A. Trejdosiewicz, L.K. (2007). CD40‐mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing. International journal of cancer, Vol.121 (6), pp. 1373-1381.  show abstract

Errington, F. Jones, J. Merrick, A. Bateman, A. Harrington, K. Gough, M. O'Donnell, D. Selby, P. Vile, R. Melcher, A. (2006). Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene therapy, Vol.13 (2), pp. 138-149.

Errington, F. Bateman, A. Kottke, T. Thompson, J. Harrington, K. Merrick, A. Hatfield, P. Selby, P. Vile, R. Melcher, A. (2006). Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clinical cancer research, Vol.12 (4), pp. 1333-1341.  show abstract

Hatfield, P. Merrick, A. Harrington, K. Vile, R. Bateman, A. Selby, P. Melcher, A. (2005). Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?. Clinical oncology, Vol.17 (1), pp. 1-11.

Merrick, A. Errington, F. Milward, K. O'Donnell, D. Harrington, K. Bateman, A. Pandha, H. Vile, R. Morrison, E. Selby, P. Melcher, A. (2005). Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming. British journal of cancer, Vol.92 (8), pp. 1450-1458.

Daniels, G.A. Sanchez-Perez, L. Diaz, R.M. Kottke, T. Thompson, J. Lai, M. Gough, M. Karim, M. Bushell, A. Chong, H. Melcher, A. Harrington, K. Vile, R.G. (2004). A simple method to cure established tumors by inflammatory killing of normal cells. Nature biotechnology, Vol.22 (9), pp. 1125-1132.

Melcher, A.A. Sebag-Montefiore, D. (2003). Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. British journal of cancer, Vol.88 (9), pp. 1352-1357.

Linardakis, E. Bateman, A. Phan, V. Ahmed, A. Gough, M. Olivier, K. Kennedy, R. Errington, F. Harrington, K.J. Melcher, A. Vile, R. (2002). Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer research, Vol.62 (19), pp. 5495-5504.

Harrington, K.J. Bateman, A.R. Melcher, A.A. Ahmed, A. Vile, R.G. (2002). Cancer Gene Therapy: Part 1 Vector Development and Regulation of Gene Expression. Clinical oncology, Vol.14 (1), pp. 3-16.

Harrington, K.J. Melcher, A.A. Bateman, A.R. Ahmed, A. Vile, R.G. (2002). Cancer Gene Therapy: Part 2 Candidate Transgenes and their Clinical Development. Clinical oncology, Vol.14 (2), pp. 148-169.

Melcher, A. Bateman, A. Harrington, K. Ahmed, A. Gough, M. Vile, R. (2002). Dendritic Cells for the Immunotherapy of Cancer. Clinical oncology, Vol.14 (3), pp. 185-192.

Turnbull, S. West, E. Scott, K. Appleton, E. Melcher, A. Ralph, C. Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. Viruses, Vol.7 (12), pp. 6291-6312.

Bradley, S. Jakes, A. Harrington, K. Pandha, H. Melcher, A. Errington-Mais, F. Applications of coxsackievirus A21 in oncology. Oncolytic virotherapy, , pp. 47-47.

Pandha, H. Simpson, G. Relph, K. Melcher, A. Harrington, K. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic virotherapy, , pp. 1-1.

Book Chapters

Comins, C. Simpson, G.R. Relph, K. Harrington, K.J. Melcher, A. Pandha, H. (2014). Reoviral Therapy for Cancer. Gene Therapy of Cancer. (pp. 185-198). Elsevier.

In this section

Professional activities Publications